Melese Hailu Legese | Bacteriology | Best Researcher Award

Published on by Global Academic Awards

Dr. Melese Hailu Legese | Bacteriology | Best Researcher Award

Dr. Melese Hailu Legese, College of Health Sciences, Addis Ababa University and Department of Biochemistry and Microbiology, Uppsala University, Ethiopia

Dr. Melese Hailu Legese is a dedicated researcher and academician affiliated with Addis Ababa University and Uppsala University. He holds a BSc in Medical Laboratory Sciences (2007) and an MSc in Diagnostic and Public Health Microbiology (2014). He completed his PhD in 2022, focusing on the genomic epidemiology of antibiotic-resistant Enterobacteriaceae in sepsis patients. Dr. Legese has authored 17 publications and collaborated with global research groups, including KlebNET-GSP and LSHTM. His work addresses antimicrobial resistance (AMR), sepsis pathogens, and genomic surveillance systems, contributing to global health. He is a member of multiple esteemed microbiology societies. βœ¨πŸ“š

 

Publication Profile

Orcid

Google Scholar

Academic and Professional Background πŸŽ“πŸ”¬πŸŒ

Dr. Melese Hailu Legese is a distinguished academic and researcher affiliated with Addis Ababa University and Uppsala University. He earned his BSc in Medical Laboratory Sciences from the University of Gondar (2007) and an MSc in Diagnostic and Public Health Microbiology from Addis Ababa University (2014). From 2017 to 2022, he pursued his PhD at Addis Ababa University, simultaneously serving as a guest doctoral researcher at Uppsala University since 2020. His research, focusing on the genomic epidemiology of antibiotic-resistant Enterobacteriaceae in sepsis patients using whole-genome sequencing, has culminated in impactful publications, international presentations, and global scientific collaborations. βœ¨πŸ“ŠπŸŒ

 

Research Focus

Dr. Melese Hailu Legese’s research focuses on the genomic analysis of sepsis pathogens and antimicrobial resistance (AMR). Leveraging cutting-edge whole-genome sequencing (WGS), he investigates the genetic mechanisms driving AMR, including resistance genes, virulence factors, and pathogen evolution. His work also encompasses the study of emerging sepsis pathogens, integrating genomic, clinical, and epidemiological data to enhance diagnostic accuracy and develop targeted antimicrobial stewardship strategies. Dr. Legese’s research addresses critical challenges in infection control and AMR, contributing significantly to global efforts in combating resistant infections, particularly in resource-limited settings. πŸŒπŸ”¬πŸ“Š

 

Publication Top Notes

  • Genomic characterizations of Klebsiella variicola: Emerging pathogens identified from sepsis patients in Ethiopian referral hospitals 🧬 (2025) – DOI: 10.1080/22221751.2024.2440494
  • Sepsis: Emerging pathogens and antimicrobial resistance in Ethiopian referral hospitals 🦠 (2022) – DOI: 10.1186/s13756-022-01122-x
  • Genomic Epidemiology of Carbapenemase-Producing and Colistin-Resistant Enterobacteriaceae among Sepsis Patients in Ethiopia: A Whole-Genome Analysis πŸ§ͺ (2022) – DOI: 10.1128/aac.00534-22
  • Molecular Epidemiology of Extended-Spectrum Beta-Lactamase and AmpC Producing Enterobacteriaceae among Sepsis Patients in Ethiopia 🧬 (2022) – DOI: 10.3390/antibiotics11020131
  • Multidrug-Resistant and Carbapenemase-Producing Enterobacteriaceae in Addis Ababa, Ethiopia 🦠 (2021) – DOI: 10.1155/2021/9999638
  • Extended-Spectrum Beta-Lactamase and AmpC Beta-Lactamase Producing Gram-Negative Bacilli in Addis Ababa πŸ§ͺ (2020) – DOI: 10.1371/journal.pone.0241984
  • Prevalence and Associated Risk Factors for Hepatitis B and C Viruses among Refugees in Gambella, Ethiopia 🩺 (2020) – DOI: 10.1186/s12889-020-08893-1
  • Extended-Spectrum Beta-Lactamase Production and Multidrug Resistance in Addis Ababa 🦠 (2019) – DOI: 10.1186/s13756-019-0488-4
  • Common Uropathogens and Antibiotic Susceptibility Patterns among Diabetic Patients πŸ§ͺ (2019) – DOI: 10.1186/s12879-018-3669-5
  • Prevalence of Intestinal Parasites among River Water Contact Individuals in Ethiopia 🌊 (2018) – DOI: 10.1371/journal.pone.0204259
  • Bacterial Profiles and Antimicrobial Resistance Patterns in Addis Ababa Hospitals 🩺 (2017) – DOI: 10.4172/0974-8369.1000408
  • Multidrug-Resistant Bacteria in Postoperative Wound Infections in Addis Ababa 🩹 (2017) – DOI: 10.21767/1989-5216.1000233
  • Patient Satisfaction with Clinical Laboratory Services in Addis Ababa 😊 (2017) – DOI: 10.2147/ppa.s132397
  • Quality Assessment of Public Swimming Pools in Addis Ababa, Ethiopia 🌊 (2017) – DOI: 10.2174/1874285801711010098

Khalid Abd El Ghany | Microbial biotechnology | Best Researcher Award

Published on by Global Academic Awards

Assist Prof Dr. Khalid Abd El Ghany | Microbial biotechnology | Best Researcher Award

Assist Prof Dr. Khalid Abd El Ghany, Egyption Drug Authoriity, Egypt

Dr. Khalid Abd El Ghany is a Post-Approval Control Manager at the Egyptian Drug Authority (since 2021) with over two decades of experience in the pharmaceutical sector. He holds a Ph.D. in Genetic Engineering and Biotechnology from Al-Sadat City University (2018) and has completed post-doctoral research at the Egyptian Drug Authority. He is a skilled researcher with numerous publications and expertise in microbial biotechnology. A recipient of the Egyptian Drug Authority Hero’s Certificate (2022) and the Ideal Pharmacist Award (2016), Dr. Khalid is also active in social initiatives, holding leadership roles in various organizations. πŸ“šπŸŒ

 

Publication profile

Google Scholar

Education Background

Dr. Khalid Abd El Ghany has a distinguished educational background in pharmacy and biotechnology. He earned his B.Sc. in Pharmacy with honors from Al-Azhar University, Egypt, in 1994. Later, he pursued an M.Sc. in Microbial Biotechnology from Al-Sadat City University (2012-2014), further advancing his expertise with a Ph.D. in Genetic Engineering and Biotechnology from the same institution in 2018. Since 2020, he has been a post-doctoral researcher at the Egyptian Drug Authority, where he continues to contribute to the field of microbial biotechnology. πŸ“˜πŸ”¬

 

Professional Experience

Dr. Khalid Abd El Ghany has extensive experience in pharmaceutical regulation and management. Since 2021, he has served as the Post-Approval Control Manager at the Egyptian Drug Authority (EDA). From 2017 to 2021, he was the Deputy Head of the Inspection Department at NODCAR, where he also worked in the Microbiology Lab from 2012 to 2017. His career began as a pharmacist at Arab Drug Company (1995-1996), followed by years in the private pharmaceutical sector, where he was the owner and director from 1996 to 2011. πŸŒŸπŸ”¬

 

Research Focus

Dr. Khalid Abd El Ghany’s research is primarily centered on microbial biotechnology and genetic engineering. His work involves probiotics, especially Lactobacillus acidophilus, in cancer treatment and antioxidant activities. He also focuses on vaccine design, integrating immunoinformatics and cheminformatics to target pathogens like Klebsiella pneumoniae and Pseudomonas aeruginosa. Additionally, Dr. Khalid has contributed to studies on Ξ²-glucan production, antimicrobial agents, and the potential of probiotics against viral infections, including COVID-19. His work is diverse, covering biotechnology, immunology, and pharmaceutical sciences. πŸ§¬πŸ’‰

 

Conclusion

With his strong academic background, significant experience in pharmaceutical regulation, a proven track record in research, and leadership in social initiatives, Assist. Prof. Dr. Khalid Abd El Ghany is a strong candidate for the Best Researcher Award. His dedication to both scientific advancement and community service makes him a well-rounded contender for this recognition.

 

Publication Top Notes

  • A potential role of Lactobacillus acidophilus LA1 and its exopolysaccharides on cancer cells in male albino mice – 43 citations (2015) πŸ“‘πŸ§¬
  • In Silico Designing of a Multitope Vaccine against Rhizopus microsporus – 26 citations (2021) πŸ’‰πŸ–₯️
  • Evaluation of antioxidant and antitumor activities of Lactobacillus acidophilus bacteria – 20 citations (2014) πŸ§ͺ🦠
  • Screening and molecular identification of lactic acid bacteria producing Ξ²-glucan – 13 citations (2022) 🧬🍏
  • Description of isolated LAB producing Ξ²-glucan and evaluation of its therapeutic effect – 11 citations (2016) 🧫🩺
  • Integration of Immunoinformatics and Cheminformatics for Vaccine Design – 5 citations (2023) πŸ§¬πŸ’‰
  • Molecular Characterization and Optimization of Ξ²-Glucan Production from Pediococcus parvulus – 3 citations (2018) πŸ§¬πŸ“Š
  • Lactiplantibacillus plantarum and Saussurea costus as Therapeutic Agents – 2 citations (2023) πŸ§¬πŸ’Š
  • Role of probiotic bacteria against virus pathogenesis: Defence against COVID-19 – 1 citation (2024) 🦠🧬
  • Efficacy of Ξ²-glucan in an acute model of diabetes – 1 citation (2022) πŸ©ΊπŸ“Š
  • Synthesis, Molecular Docking Studies of Pyrazolo[1,5-a]pyrimidines – 2023 πŸ“‘βš—οΈ